Header

Pancreatic Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 22 Trial

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca

The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with p...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase: 3

Protocol Number: 16-146

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer

Phase: 2

Protocol Number: 15-547

Gemcitabine Plus BPM31510 Administered Intravenously in Advanced Pancreatic Cancer Patients

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of the combination of BPM31510 administered as a 144-hour continuous intravenous (IV) infusio...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase: 2

Protocol Number: 17-066

Safety and Efficacy of FGF401 in Patients With Solid Malignancies

Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies

Diagnosis: Gastrointestinal Malignancies, Stomach Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer

Phase: 1 / 2

Protocol Number: 14-464

A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer

This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refract...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer, Colorectal Cancer

Phase: 1

Protocol Number: 17-137

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 15-191

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)

This study will assess the efficacy and safety of BL-8040 as a single agent and in combination with pembrolizumab (Keytruda®) in subjects with metastatic pancreatic adenocarcinoma.

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 16-508

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations

Diagnosis: Pancreatic Cancer

Phase:

Protocol Number: 16-448

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surg...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 16-490

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. ...

Diagnosis: Colorectal Cancer, Pancreatic Cancer

Phase:

Protocol Number: 17-021

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

The purpose of this study is to compare any good and bad effects of using chemotherapy compared to chemotherapy and radiation prior to surgery. This study will allow the researchers to know whether...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 17-047

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with P...

Diagnosis: GYN: Endometrial/Uterine Cancer, Melanoma, Pancreatic Cancer, Breast: Early Stage Disease

Phase:

Protocol Number: 16-491

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcin...

Diagnosis: Pancreatic Cancer

Phase:

Protocol Number: 17-326

Physical Activity In Gastrointestinal Cancer

This research study is evaluating the ability for people with metastatic gastrointestinal cancer to participate in a physical activity program.

Diagnosis: Pancreatic Cancer, Colorectal Cancer, Gastrointestinal Malignancies, Esophageal Cancer

Phase:

Protocol Number: 17-350

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinati...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 17-429

A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)

To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with ...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 17-169

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

This research study is evaluating a study drug to treat pancreatic exocrine insufficiency (PEI) during the first year after the diagnosis of pancreatic cancer while the participant is recovering fr...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 17-450

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with KRAS G12R mutations that has spread from where it started to nearby tissue or lymph n...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 18-710

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

This will be a Phase 1a/2b multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metas...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 17-665

The GI Binder: A Psychoeducational Intervention for Pancreatic Cancer Patients

This research study is evaluating the use of a binder of educational materials with nurse teaching to prepare patients for chemotherapy

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 18-241

GENetic Education Risk Assessment and TEsting Study

The goal of the GENERATE study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients with identified genetic mutations (inherited changes). The study w...

Diagnosis: Pancreatic Cancer

Phase:

Protocol Number: 18-222

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivoluma...

Diagnosis: Pancreatic Cancer

Phase:

Protocol Number: 18-722

'